Repetitive profound thrombocytopenia after treatment with tirofiban: A case report

Cardiovascular Drugs and Therapy

Volumn 18, Issue 6, 2004, Pages 503-505

  Eryonucu, Beyhan ^a   Tuncer, Mustafa ^a   Erkoc, Reha ^a  

^a YUZUNCU YIL UNIVERSITY   (Turkey)

Author keywords

Thrombocytopenia; Tirofiban

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; CLOPIDOGREL; HEPARIN; TIROFIBAN;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; HEART INFARCTION; HUMAN; MALE; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ANGIOPLASTY, BALLOON; ARTERIAL OCCLUSIVE DISEASES; ASPIRIN; DRUG ADMINISTRATION SCHEDULE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; STENTS; THROMBOCYTOPENIA; TICLOPIDINE; TYROSINE;

EID: 16844371368     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10557-004-6228-9     Document Type: Article

References (10)

1. Karvouni E, Katritsis DG, Ioannidis J. Intravenous glycoprotein IIb/IIIa receptor antagonists reduce mortality after percutaneous coronary interventions. J Am Coll Cardiol 2003;41:26-32.
2. Boersma E, Harrington RA, Moliterno DJ, et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: A meta-analysis of all major randomised clinical trials. Lancet 2002;359:189-198.
3. Abrams CS, Cines DB. Thrombocytopenia after treatment with platelet glycoprotein IIb/IIIa inhibitors. Curr Hematol Rep. 2004;3:143-147.
4. Dasgupta H, Blankenship JC, Wood GC, Frey CM, Demko L, Menapace FJ. Thrombocytopenia complicating treatment with intravenous glycoprotein IIb/IIIa receptor inhibitors: A pooled analysis. Am Heart J 2000;140:206-211.
5. Merlini PA, Rossi M, Menozzi A, et al. Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting. Circulation 2004;109(18):2203-2206.
6. Tcheng JE. Clinical challenges of platelet glycoprotein IIb/IIIa receptor inhibitor therapy: Bleeding, reversal, thrombocytopenia, and re-treatment. Am Heart J 2000;139:S38-S45.
7. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30(2):239-245.
8. Bougie DW, Wilker PR, Wuitschick ED, et al. Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIa. Blood 2002;100:2071-2076.
9. Curtis B, Swyers J, Divgi A, McFarland J, Aster R. Thrombocytopenia after second exposure to abciximab is caused by antibodies that recognize abciximabcoated platelets. Blood 2002;99:2054-2059.
10. Topol EJ, Moliterno DJ, Herrmann HC, et al. for the TARGET Investigators. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. New Engl J Med 2001;344:1888-1894.